ClinicalTrials.gg

Program

bepirovirsen

Also written as “Bepirovirsen”, “GSK3228836” and “IONIS-HBVRx”.

Its studies are mostly in Hepatitis B · Hepatitis B, Chronic, led by GlaxoSmithKline.

Furthest: phase 4, since Oct 26, 202615 company-led studies, 5 open or runningNext primary completion: Mar 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline155 open or runningphase 4since Oct 26, 2026Dec 1, 2016Mar 30, 2027phase 1 · NCT07905157

Also a collaborator on its studies: ppd-development-lp and Ionis Pharmaceuticals.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 1, 2016First study: phase 2 study in Hepatitis BFirst studyNCT02981602 · 31 enrolled · Hong Kong, Korea, Republic of
  2. Jun 23, 2020Phase 2 study in Hepatitis BNCT04449029 · 457 enrolled · United States, Argentina, Bulgaria and more
  3. Sep 4, 2020Phase 2 study in Hepatitis BNCT04544956 · 12 enrolled · United States, Canada, Netherlands and more
  4. Dec 15, 2020Phase 2 study in Hepatitis BNCT04676724 · 108 enrolled · United States, Canada, China and more
  5. Jun 22, 2021Phase 1 study in Hepatitis BNCT04971928 · 24 enrolled · United States
  6. Jun 29, 2021Phase 2 study in Hepatitis BNCT04954859 · 366 enrolled · United States, Argentina, Australia and more
  7. Apr 8, 2022Phase 2 study in Hepatitis BNCT05330455 · 74 enrolled · Canada, France, Italy and more
  8. Nov 21, 20222 phase 3 studies in Hepatitis B, ChronicNCT05630820, NCT05630807
  9. Sep 22, 2023Phase 1 study in Hepatitis BNCT06058390 · 160 enrolled · United States
  10. May 15, 2024Phase 1 study in Hepatitis BNCT06422767 · 46 enrolled · United States
  11. Jul 5, 2024Phase 2 study in Hepatitis BNCT06497504 · 153 enrolled · United States, Argentina, Brazil and more
  12. Sep 10, 2025Phase 1 study in Hepatitis BNCT07168356 · 32 enrolled · United States
  13. Oct 23, 2026Phase 1 study in Hepatitis BNCT07905157 · 98 planned
  14. Oct 26, 2026Phase 4 study in Hepatitis BNCT07908459 · 303 planned

Ahead

  1. Mar 30, 2027Primary completion: phase 1 study in Hepatitis BNCT07905157
  2. Apr 22, 2027Primary completion: phase 2 study in Hepatitis BNCT06497504
  3. Jan 24, 2029Primary completion: phase 2 study in Hepatitis BNCT04954859
  4. Dec 3, 2030Primary completion: phase 4 study in Hepatitis BNCT07908459

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“mRNA antisense inhibitor”ChEMBL 37, by rule

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07908459Hepatitis B4Not yet recruitingDec 3, 2030303
NCT07905157Hepatitis B1Not yet recruitingMar 30, 202798
NCT07168356Hepatitis B · United States1Active, not recruitingMar 3, 202632
NCT06497504Hepatitis B · United States, Argentina, Brazil and more2Active, not recruitingApr 22, 2027153
NCT06422767Hepatitis B · United States1CompletedApr 28, 202546
NCT06058390Hepatitis B · United States1CompletedMay 3, 2024160
NCT05630820Hepatitis B, Chronic · United States, Argentina, Australia and more3CompletedNov 3, 2025857
NCT05630807Hepatitis B, Chronic · United States, Argentina, Brazil and more3CompletedNov 11, 2025981
NCT05330455Hepatitis B · Canada, France, Italy and more2TerminatedMay 19, 202574
NCT04954859Hepatitis B · United States, Argentina, Australia and more2Active, not recruitingJan 24, 2029366
NCT04971928Hepatitis B · United States1CompletedMay 12, 202224
NCT04676724Hepatitis B · United States, Canada, China and more2CompletedFeb 17, 2023108
NCT04544956Hepatitis B · United States, Canada, Netherlands and more2CompletedNov 30, 202312
NCT04449029Hepatitis B · United States, Argentina, Bulgaria and more2CompletedMar 18, 2022457
NCT02981602Hepatitis B · Hong Kong, Korea, Republic of2CompletedDec 18, 201931

How it is read

Names in the registry

  • “Bepirovirsen”, 10 entries
  • “GSK3228836”, 4 entries
  • “IONIS-HBVRx”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.